These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31855703)

  • 1. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Sands JM; Nguyen T; Shivdasani P; Sacher AG; Cheng ML; Alden RS; Jänne PA; Kuo FC; Oxnard GR; Sholl LM
    Lung Cancer; 2020 Feb; 140():35-41. PubMed ID: 31855703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Lam VK; Tran HT; Banks KC; Lanman RB; Rinsurongkawong W; Peled N; Lewis J; Lee JJ; Roth J; Roarty EB; Swisher S; Talasaz A; Futreal PA; Papadimitrakopoulou V; Heymach JV; Zhang J
    Clin Lung Cancer; 2019 Jan; 20(1):30-36.e3. PubMed ID: 30279110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
    Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
    J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.
    Seto K; Masago K; Fujita S; Haneda M; Horio Y; Hida T; Kuroda H; Hosoda W; Okubo KI
    Thorac Cancer; 2020 Jul; 11(7):1827-1834. PubMed ID: 32372482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
    Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing in lung cancer: An initial experience from India.
    Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
    Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.